TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35123460

Group type: EXPERIMENTAL
Intervention: Three-dimensional corrective exercise therapy (TDCET)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Generalized exercise therapy (Control Group)
Number of subjects: 144
Study: 35123544

Group type: EXPERIMENTAL
Intervention: Setmelanotide
Number of subjects: 21
Study: 35123562

Group type: EXPERIMENTAL
Intervention: Veno-venous ECMO for COVID-19
Number of subjects: 308

Group type: COMPARATOR
Intervention: Veno-venous ECMO for H1N1
Number of subjects: 308
Study: 35123583

Group type: EXPERIMENTAL
Intervention: Enhanced cognitive behavioral therapy (CBT-E), 40 sessions
Number of subjects: 33
Study: 35123640

Group type: EXPERIMENTAL
Intervention: Steroids-Ruxolitinib
Number of subjects: 23

Group type: COMPARATOR
Intervention: Steroids
Number of subjects: 23

Group type: COMPARATOR
Intervention: Free-aGVHD
Number of subjects: 23
Study: 35123771

Group type: EXPERIMENTAL
Intervention: Navitoclax (ABT-737 analogue) monotherapy at 150 mg daily for 7-14 days, then increased to 250 mg daily
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Navitoclax (ABT-737 analogue) monotherapy
Number of subjects: 46
Study: 35123853

Group type: EXPERIMENTAL
Intervention: Inflammatory food index (IFI) score, adjusted for multiple covariates
Number of subjects: 9909

Group type: EXPERIMENTAL
Intervention: Inflammatory food index (IFI) score, adjusted for sociodemographic factors
Number of subjects: 9909
Study: 35123868

Group type: EXPERIMENTAL
Intervention: Youth-onset type 2 diabetes (T2D)
Number of subjects: 677
Study: 35124074

Group type: EXPERIMENTAL
Intervention: Hemospray (hemostatic powder)
Number of subjects: 67
Study: 35124236

Group type: EXPERIMENTAL
Intervention: BMS-LM core ontology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMS-LM data model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Top/core/domain/local ontological levels
Number of subjects: 0
Study: 35124411

Group type: EXPERIMENTAL
Intervention: Platinum doublet chemoradiation (Cohort 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Platinum doublet cytotoxic chemotherapy ± immunotherapy (Cohort 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Palliative radiation (Cohort 3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Post-treatment samples (all cohorts)
Number of subjects: 40
Study: 35124680

Group type: EXPERIMENTAL
Intervention: Transcutaneous PCO2 measurement
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Transcutaneous PO2 measurement
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Transcutaneous blood gas measurement system
Number of subjects: 110
Study: 35124888

Group type: EXPERIMENTAL
Intervention: FAME-iSS intervention (Fatigue and Activity Management Education in Systemic Sclerosis) for 6 weeks
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: FAME-iSS intervention
Number of subjects: 4
Study: 35125401

Group type: EXPERIMENTAL
Intervention: Everolimus (2L targeted therapy)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Axitinib (2L targeted therapy)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sunitinib (1L targeted therapy)
Number of subjects: 27
Study: 35125476

Group type: EXPERIMENTAL
Intervention: Alcohol interactive toxicity beliefs
Number of subjects: 408
Study: 35126362

Group type: EXPERIMENTAL
Intervention: mRNA-1273 at a dose of 25 μg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: mRNA-1273 at a dose of 100 μg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ACOV2S measurements
Number of subjects: 30
Study: 35126471

Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T-Cell Therapy
Number of subjects: 0
Study: 35126524

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous (IV) rituximab
Number of subjects: 0
Study: 35127744

Group type: EXPERIMENTAL
Intervention: Lung ultrasound evaluation (LUS)
Number of subjects: 0
Study: 35127778

Group type: EXPERIMENTAL
Intervention: DHA algae oil supplement (3.15 g daily for 6 months)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 35128142

Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation (HF-rTMS)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: HF-rTMS and iTBS
Number of subjects: 90
Study: 35128365

Group type: EXPERIMENTAL
Intervention: Sayana Press injected every 4 months (3 treatment cycles) for 12 months
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Sayana Press injected in the abdomen
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Sayana Press injected in the thigh
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Sayana Press injected in the arm
Number of subjects: 750
Study: 35128367

Group type: EXPERIMENTAL
Intervention: PrEP acceptability
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: PrEP initiation/uptake
Number of subjects: 542
Study: 35128512

Group type: EXPERIMENTAL
Intervention: rAd5
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: ChAdOx1
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: rAd26
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: mRNA-1273
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: BBIBP-CorV
Number of subjects: 540

Group type: COMPARATOR
Intervention: Serum neutralizing capacity
Number of subjects: 540

Group type: COMPARATOR
Intervention: Safety outcome
Number of subjects: 540
Study: 35128529

Group type: EXPERIMENTAL
Intervention: High-dose split-virus influenza vaccine (HD-SVV)
Number of subjects: 582

Group type: COMPARATOR
Intervention: Standard dose split-virus influenza vaccine (SD-SVV)
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: All groups (HD-SVV, SD-SVV)
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Prior season influenza vaccination
Number of subjects: 582
Study: 35128939

Group type: EXPERIMENTAL
Intervention: Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide; specific dosage and duration not mentioned
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; details not available
Number of subjects: 0
Study: 35129007

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35129069

Group type: EXPERIMENTAL
Intervention: Gamitrinib, a mitochondria-targeted small molecule Hsp90 inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35129146

Group type: EXPERIMENTAL
Intervention: MRD assessment with real time quantitative polymerase chain reaction (qPCR) in 283 patients
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: MRD assessment with multiparametric flow cytometry (MFC)-MRD in 107 patients
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: PCR-MRD ≥10-3 on day 78
Number of subjects: 1388
Study: 35129211

Group type: EXPERIMENTAL
Intervention: Binocular treatment
Number of subjects: 68

Group type: COMPARATOR
Intervention: Patching treatment
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 68
Study: 35129214

Group type: COMPARATOR
Intervention: Valproic acid
Number of subjects: 856

Group type: COMPARATOR
Intervention: Diazepam (3-day treatment)
Number of subjects: 856
Study: 35129282

Group type: EXPERIMENTAL
Intervention: Leflunomide-induced liver injury in Indian patients (n=16)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Teriflunomide-induced liver injury in US patients (n=1)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Comparison of Indian cohort vs US DILIN patients
Number of subjects: 17
Study: 35129301

Group type: EXPERIMENTAL
Intervention: Disclosure to partners (diagnosed prior to current pregnancy)
Number of subjects: 1392

Group type: EXPERIMENTAL
Intervention: Disclosure to partners (diagnosed during current pregnancy)
Number of subjects: 1392
Study: 35129317

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after 3-month dual antiplatelet therapy (DAPT)
Number of subjects: 2980

Group type: COMPARATOR
Intervention: Ticagrelor-based 12-month DAPT
Number of subjects: 2980
Study: 35129374

Group type: EXPERIMENTAL
Intervention: Once-daily oral cabotegravir 30 mg for 4 weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Five 600-mg (3-mL) intramuscular cabotegravir LA injections at weeks 5, 9, 17, 25, and 33
Number of subjects: 47

Group type: COMPARATOR
Intervention: Daily oral standard-of-care
Number of subjects: 47
Study: 35129407

Group type: EXPERIMENTAL
Intervention: VenoValve implantation
Number of subjects: 11
Study: 35129457

Group type: EXPERIMENTAL
Intervention: Peer counseling intervention starting in late pregnancy up to 1 year after delivery.
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Peer counseling intervention
Number of subjects: 1056

Group type: COMPARATOR
Intervention: Control group (no peer counseling)
Number of subjects: 1056
Study: 35129466

Group type: EXPERIMENTAL
Intervention: Intensive Surveillance (IS) - defined as annual computed tomography for 3 years postoperatively
Number of subjects: 4682

Group type: EXPERIMENTAL
Intervention: Intensive Surveillance (IS)
Number of subjects: 4682
Study: 35129472

Group type: EXPERIMENTAL
Intervention: Intrathoracic implantation of multidrug-eluting microdevices (IMDs) containing 12 chemotherapeutic agents, inserted intraoperatively and retrieved with the resected specimen.
Number of subjects: 5
Study: 35129514

Group type: EXPERIMENTAL
Intervention: ALPPS (Associating Liver Partition and Portal vein ligation for Staged hepatectomy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TSH (Two-stage hepatectomy)
Number of subjects: 0
Study: 35129526

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) using Dexcom G6
Number of subjects: 70
Study: 35129803

Group type: EXPERIMENTAL
Intervention: Ocrelizumab infusion after first-line immunotherapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 35129995

Group type: EXPERIMENTAL
Intervention: Laboratory context
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment (EMA) context
Number of subjects: 45
Study: 35130025

Group type: EXPERIMENTAL
Intervention: Maternal diabetes
Number of subjects: 1812

Group type: COMPARATOR
Intervention: No maternal diabetes
Number of subjects: 1812

Group type: EXPERIMENTAL
Intervention: Maternal diabetes or obesity
Number of subjects: 1812
Study: 35130292

Group type: EXPERIMENTAL
Intervention: Treatment for acute leukaemia during pregnancy; specific details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Successful treatment of acute leukaemia prior to pregnancy; specific details on treatment not available.
Number of subjects: 0
Study: 35130339

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (RUX)
Number of subjects: 209
Study: 35130417

Group type: COMPARATOR
Intervention: Chemotherapy maintenance
Number of subjects: 3867

Group type: COMPARATOR
Intervention: Chemotherapy maintenance for hormone receptor-positive MBC patients
Number of subjects: 3867

Group type: COMPARATOR
Intervention: Endocrine therapy maintenance for hormone receptor-positive MBC patients
Number of subjects: 3867

Group type: COMPARATOR
Intervention: Chemotherapy vs Endocrine therapy maintenance
Number of subjects: 3867
Study: 35130491

Group type: EXPERIMENTAL
Intervention: Severe global CRF (score of ≥40/100)
Number of subjects: 7902

Group type: EXPERIMENTAL
Intervention: Severe physical CRF
Number of subjects: 7902

Group type: EXPERIMENTAL
Intervention: Severe emotional CRF
Number of subjects: 7902
Study: 35130505

Group type: EXPERIMENTAL
Intervention: Patients with NSCLC at diagnosis
Number of subjects: 76

Group type: COMPARATOR
Intervention: Community controls, n=67
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Patients with NSCLC
Number of subjects: 76
Study: 35130557

Group type: EXPERIMENTAL
Intervention: Intracerebral stem cell delivery using a frame-based stereotactic delivery system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalizable protocol for intracerebral trajectory planning
Number of subjects: 0
Study: 35130909

Group type: EXPERIMENTAL
Intervention: Plasma apolipoprotein concentrations
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Plasma apoE levels
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Apolipoproteins (apoF, apoJ, apoL1)
Number of subjects: 307
Study: 35130943

Group type: EXPERIMENTAL
Intervention: Trametinib 2 mg QD in Mild HD patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Trametinib 1.5 mg QD in Moderate HD patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Trametinib 1 mg QD in Severe HD patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Trametinib (various doses)
Number of subjects: 46
Study: 35131031

Group type: EXPERIMENTAL
Intervention: Pulmonary computed tomography (CT) and lung function (LF) assessments at 60, 100, and 180 days follow-up.
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Pulmonary computed tomography (CT) assessments.
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Lung function (LF) assessments.
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Clustering and machine learning classifiers using non-CT and non-LF parameters.
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Assessment of anti-S1/S2 antibody titer, IL-6, and CRP levels.
Number of subjects: 145
Study: 35131040

Group type: EXPERIMENTAL
Intervention: Niraparib 300 mg orally once daily until treatment discontinuation, death, or study termination.
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 289
Study: 35131254

Group type: EXPERIMENTAL
Intervention: Topical ruxolitinib applied twice daily for 8 weeks
Number of subjects: 12
Study: 35131513

Group type: EXPERIMENTAL
Intervention: Direct oral challenge for penicillin allergy delabeling
Number of subjects: 0
Study: 35131555

Group type: EXPERIMENTAL
Intervention: Preoperative oximetry-derived hypoxemia (ODI ≥30 events/hour)
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Preoperative screening using oximetry
Number of subjects: 1218
Study: 35131660

Group type: EXPERIMENTAL
Intervention: Person-centered behavioral strategies used by staff (41.9% modifications of resident abilities, 35.1% care approaches, 13.6% dining environment)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Challenging behaviors exhibited by residents (35.7% resistive behaviors, 33.5% chewing/swallowing difficulties, 9.9% functional impairments, 20.9% positive/neutral behaviors)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Correlation between residents' challenging behaviors and staff person-centered behavioral strategies
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Dyadic nonverbal behaviors
Number of subjects: 110
Study: 35131826

Group type: EXPERIMENTAL
Intervention: WHO Safe Childbirth Checklist implementation
Number of subjects: 1559

Group type: COMPARATOR
Intervention: Coaching-based implementation of the WHO Checklist
Number of subjects: 1559
Study: 35131835

Group type: EXPERIMENTAL
Intervention: Advanced HIV disease (AHD) care package implementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD4 test, tuberculosis-lipoarabinomannan assay, cryptococcal antigen lateral flow assay
Number of subjects: 0
Study: 35131875

Group type: EXPERIMENTAL
Intervention: PCA062 at 3.6 mg/kg every 2 weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: PCA062 at various dose levels (0.4 to 5.0 mg/kg every 2 weeks)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: PCA062
Number of subjects: 47
Study: 35131903

Group type: COMPARATOR
Intervention: Olaparib maintenance monotherapy (300 mg orally twice daily until disease progression or unacceptable toxicity)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Olaparib maintenance monotherapy
Number of subjects: 225
Study: 35132264

Group type: EXPERIMENTAL
Intervention: Epidural electrical stimulation (EES) targeting the dorsal roots of lumbosacral segments
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Activity-specific stimulation programs
Number of subjects: 3
Study: 35132679

Group type: EXPERIMENTAL
Intervention: RsqVd (lenalidomide, subcutaneous bortezomib, and dexamethasone)
Number of subjects: 88
Study: 35132704

Group type: EXPERIMENTAL
Intervention: Lanreotide autogel (LAN) 120 mg/28 days for 1 year
Number of subjects: 50
Study: 35132840

Group type: EXPERIMENTAL
Intervention: Morning chronotype
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study: 35133093

Group type: EXPERIMENTAL
Intervention: AI-based CADe/x
Number of subjects: 32714

Group type: COMPARATOR
Intervention: Standard mammography readings without AI-based CADe/x
Number of subjects: 32714
Study: 35133112

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 0
Study: 35133199

Group type: EXPERIMENTAL
Intervention: Sodium MRI measuring CMG dynamics after water load in healthy volunteers
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium MRI measuring CMG in participants with chronic kidney disease (CKD)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Urinary osmolarity
Number of subjects: 15
Study: 35133221

Group type: EXPERIMENTAL
Intervention: Pomalidomide, dexamethasone, and daratumumab
Number of subjects: 0
Study: 35133471

Group type: EXPERIMENTAL
Intervention: Insufficient sleep (5 h/night)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Recovery sleep
Number of subjects: 12
Study: 35133604

Group type: EXPERIMENTAL
Intervention: General Health Questionnaire (GHQ-28 items)
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Age group 41 to 59 years
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Patients affected by cancer
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Patients without previous psychiatric treatment
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Patients with relatives affected by cancer
Number of subjects: 766
Study: 35133636

Group type: EXPERIMENTAL
Intervention: Aclidinium/formoterol 400/12 µg twice daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aclidinium
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 20
Study: 35133640

Group type: EXPERIMENTAL
Intervention: Telemonitoring group (TMG)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 256
Study: 35133982

Group type: EXPERIMENTAL
Intervention: Paclitaxel chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy without CIPN
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 35134165

Group type: EXPERIMENTAL
Intervention: T2Candida assay
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: T2Candida and Platelia Candida Ag Plus assays (combined)
Number of subjects: 500
Study: 35134259

Group type: EXPERIMENTAL
Intervention: Avatrombopag 40 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Avatrombopag 60 mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 35134662

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPET) on a treadmill and exercise stress echocardiography on a lower limb cycle ergometer
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPET)
Number of subjects: 31
Study: 35134821

Group type: EXPERIMENTAL
Intervention: Abbott Freestyle Libre Pro (FSL) devices
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Dexcom G6
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Paired CGMs
Number of subjects: 394
Study: 35134880

Group type: EXPERIMENTAL
Intervention: Ibezapolstat 450 mg orally every 12 hours for 10 days
Number of subjects: 10
Study: 35134954

Group type: EXPERIMENTAL
Intervention: Xpert® Xpress Flu/RSV assay
Number of subjects: 561

Group type: COMPARATOR
Intervention: RT-PCR
Number of subjects: 561
Study: 35135065

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 651
Study: 35135470

Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA vaccine
Number of subjects: 0
Study: 35135499

Group type: EXPERIMENTAL
Intervention: Booklet-based intervention for diabetic hypoglycaemia (Hypos can strike twice)
Number of subjects: 159
Study: 35135644

Group type: EXPERIMENTAL
Intervention: Vaccinated with CoronaVac
Number of subjects: 90
Study: 35135700

Group type: EXPERIMENTAL
Intervention: MMR vaccination (two doses)
Number of subjects: 2
Study: 35135810

Group type: EXPERIMENTAL
Intervention: Neoadjuvant intratumoral immunotherapy with TLR9 ligand CpG and anti-OX40 antibody
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant intratumoral immunotherapy with TLR9 ligand CpG and anti-OX40 antibody plus systemic anti-PD1 antibody
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant checkpoint blockade therapy (systemic)
Number of subjects: 0
Study: 35135824

Group type: EXPERIMENTAL
Intervention: CCEDRRN COVID-19 Mortality Score
Number of subjects: 8761
Study: 35135832

Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 vaccine (CoronaVac)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Number of DMARD
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Age (5-year interval)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Prednisone >7.5 mg/day
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: DMARD combinations
Number of subjects: 260
Study: 35135966

Group type: EXPERIMENTAL
Intervention: Early nonreactive EEG
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Discontinuous EEG background
Number of subjects: 52
Study: 35136124

Group type: EXPERIMENTAL
Intervention: Self-reported symptom assessment of smell and taste loss
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Self-ratings of chemosensory function
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Multivariate analysis of predictors
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Perceived nasal obstruction
Number of subjects: 498
Study: 35136603

Group type: EXPERIMENTAL
Intervention: Allogeneic CD20-targeted γδ T cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Autologous chimeric antigen receptor (CAR) αβ T-cell therapies
Number of subjects: 0
Study: 35136878

Group type: EXPERIMENTAL
Intervention: Connected Ovulation Test System
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0